CROWELL NANCY M 4

4 · RENOVIS INC · Filed Feb 11, 2004

Form 4

Period: 2004-02-10

Director

Transactions

Conversion
Common Stock
2004-02-10+47,380→ 47,380 total(indirect: By Fund)
Conversion
Series C Preferred Stock
2004-02-10−1,607,647→ 0 total(indirect: By Fund)
→ Common Stock (357,255 underlying)
Conversion
Series C Preferred Stock
2004-02-10−97,174→ 0 total(indirect: By Fund)
→ Common Stock (21,594 underlying)
Conversion
Common Stock
2004-02-10+783,850→ 783,850 total(indirect: By fund)
Conversion
Series E Preferred Stock
2004-02-10−1,919,678→ 0 total(indirect: By Fund)
→ Common Stock (426,595 underlying)
Conversion
Series E Preferred Stock
2004-02-10−116,036→ 0 total(indirect: By Fund)
→ Common Stock (25,786 underlying)

Footnotes (8)

[F1]Reflects the 1-for-4.5 reverse stock split effected prior to the effectiveness of the Issuer's initial public offering.
[F2]The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest in the named trust, and the inclusion of these shares shall not be deemed an admission of beneficial ownership of all the reported shares for purpose of Section 16 for any other purpose.
[F3]AGTC Advisors Fund, L.P.
[F4]Applied Genomic Technology Capital Fund, L.P.
[F5]Each one share of Series C Preferred Stock automatically converted into 1.21773015099854 shares of Common Stock upon the closing of the Issuer's initial public offering
[F6]Does not reflect the 1-for-4.5 reverse stock split effected prior to the effectiveness of the Issuer's initial public offering.
[F7]Expiration date is irrelevant.
[F8]Each one share of Series E Preferred Stock automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.

Documents

1 file